HER2-positive breast cancer and dual-target therapy study
Part of Cancer, Skin clinical trials.
This study looks at how well a combination of two targeted drugs (trastuzumab and pertuzumab) works for people with HER2-positive breast cancer that hasn't spread. It aims to understand how HER2 levels affect treatment outcomes after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with primary breast cancer that is stage I, II, or III (has not spread to distant organs).
- Your cancer is HER2-positive, confirmed by a special test (FISH) showing a high HER2/CEP17 ratio.
- You have received at least one dose of trastuzumab and pertuzumab together, either before or after surgery.
- You had surgery to remove your breast cancer (either mastectomy or breast-conserving surgery).
- You have not had previous anti-HER2 treatment before starting this dual-target therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at different types of HER2-positive breast cancer to learn more about the disease. It is for people with early-stage or locally advanced breast cancer who have not yet received treatment, and aims to help doctors find better ways to personalize care.
This study tests whether using PET scans (a special imaging technique) to monitor how your HER2-positive breast cancer responds to treatment before surgery can help doctors choose the best treatment plan for you. The goal is to improve outcomes by personalizing therapy based on how your tumor responds.
This trial tests a new combination of two targeted drugs (Trastuzumab Rezetecan and Pertuzumab) given before surgery for HER2-positive breast cancer. The goal is to see if this approach shrinks tumors more effectively.
This Phase 3 study tests giving trastuzumab and pertuzumab as additional (adjuvant) treatment after you had those same medicines before surgery but still had remaining cancer. It may help lower the chance that HER2-positive breast cancer comes back.
This Phase 2 study tests a shorter schedule of trastuzumab and pertuzumab combined with chemotherapy (taxanes) to reduce breast cancer coming back after surgery. It mainly helps people with early-stage, HER2-positive breast cancer that has not spread, by testing whether a shorter plan still works well and is tolerable.
This study looks at how well the drug Enhertu works for patients with HER2-low breast cancer that has spread. If you are already planning to start Enhertu, researchers will collect data from your regular care to learn more about its effectiveness.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.